Aim: To study the effectiveness and safety of empagliflozin as a preoperative preparation tool, as well as to improve the long-term prognosis of planned percutaneous coronary interventions in patients with type 2 diabetes
Patients with type 2 diabetes will be randomized into 2 groups using the envelope method. One group will receive empagliflozin 10 mg 1 month before planned percutaneous coronary interventions and for 12 months thereafter in addition to previously taken hypoglycemic therapy. Patients of the second group will continue to take previously prescribed hypoglycemic therapy. Thus, the safety and effectiveness of empagliflozin for preoperative preparation of patients with type 2 diabetes before planned percutaneous coronary interventions will be evaluated, as well as the impact on the immediate and long-term outcomes of percutaneous coronary interventions in comparison with patients on standard hypoglycemic therapy
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
40
Patients from treatment group received empagliflozin 10 mg daily additionally to previously prescribed diabetes medication
hypoglycemic therapy.
glomerular filtration rate(GFR)
The glomerular filtration rate(GFR) will be measured at each visit. GFR more than 60 will be recognized as normal.
Time frame: baseline-24 weeks
HbA1C level
The HbA1C will be measured (in %) at each visit. HbA1C less than 6.1% will be recognized as normal.
Time frame: baseline-24 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.